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Context: Liraglutide is aglucagon-likepeptide-1analogandglucose-loweringagentwhoseeffects
on cardiovascular risk markers have not been fully elucidated.
Objective:Weevaluated the effect of liraglutide onmarkers of oxidative stress, hemeoxygenase-1
(HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM).
DesignandSetting:Aprospectivepilot studyof2months’ durationhasbeenperformedat theUnit
of Diabetes and Cardiovascular Prevention at University of Palermo, Italy.
Patientsand Intervention(s):Twenty subjectswithT2DM(10menand10women;meanage:5713y)
were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin
(1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded.
Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-
shock proteins, including HO-1 were assessed.
Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin
(HbA1c) (8.5 0.4 vs 7.5 0.4%, P .0001). In addition, plasma ghrelin and glutathione concen-
trations increased (8.2 4.1 vs 13.6 7.3 pg/ml, P .0007 and 0.36 0.06 vs 0.44 0.07 nmol/ml,
P  .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11  0.05 vs
0.04 0.07 pg/ml, P .0487 and7.7 7.7 vs 3.6 1.8 pg/ml, P .0445, respectively). These changes
were not correlated with changes in fasting glycemia or HbA1c.
Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin re-
sulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in
patients with T2DM. These findings seemed to be independent of the known effects of liraglutide
on glucose metabolism. (J Clin Endocrinol Metab 100: 603–606, 2015)
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Glucagon-like peptide-1 (GLP-1) analogs such as lira-glutide have been shown to be effective therapeutic
agents for type 2 diabetes mellitus (T2DM). They may
have beneficial metabolic actions that can potentially re-
duce cardiovascular risk (1), independent of their antihy-
perglycemic effect. These includeweight loss and decrease
in oxidative stress.
A known effect of liraglutide is promotion of weight
loss, thought to be mediated by induction of satiety and
retardation of gastric emptying (2). In animal models (3)
liraglutide regulated plasma ghrelin concentrations inde-
pendently of GLP-1 levels. Given that ghrelin is known to
regulate food intake, energy expenditure, and appetite (4),
the effects of liraglutide on bodyweight could bemediated
by its effects on ghrelin. In experimental animals, liraglu-
tide has been shown to also decrease oxidative stress in-
dependent of its glucose-lowering effects (5), an effect that
may contribute to decreasing atherogenesis and cardio-
vascular risk.
Markers of oxidative stress such as reactive oxygen spe-
cies (ROS), lipid hydroperoxides (LOOH), heme oxygen-
ase-1 (HO-1), and gluthatione (GSH) are abnormal in
T2DM subjects (6). Liraglutide’s specific actions on the
above-mentioned parameters are largely unknown, with
the exception of sparse data from animal models and a
brief research letter in patientswith T2DM(7). Therefore,
the goal of the present study was to investigate potential
nonglycemic effects of liraglutide that may reduce cardio-
vascular risk, including those on oxidative stress and
plasma concentrations of ghrelin, in patients with T2DM.
Materials and Methods
Patients and methods
We studied 20 subjects with T2DM whose clinical charac-
teristics are reported in Table 1. All subjects were naïve to in-
cretin-based therapies andwere takingmetformin (doses ranging
from 1500–2000mg/d) only. Liraglutide was given sc (0.6 mg/d
for 2wk, followedby 1.2mg/d) for 2months. Themean glycated
hemoglobin (HbA1c) was 8.5  0.4% and none of the subjects
had known diabetic complications or clinical evidence of car-
diovascular disease. The study design included a medical exam-
ination and biochemical analyses. The procedures adopted were
in agreement with the Helsinki Declarations and were approved
by theEthicsCouncil of theUniversity of Palermo.The studywas
registered in clinicaltrials.gov (NCT01715428).
All patients gave written informed consent to participate in
the study. They underwent a medical examination and were ex-
cluded if they had clinical evidence of liver dysfunction or renal
failure. Waist circumference, height, and weight were recorded,
and body mass index (BMI) was calculated as kg/m2. Patients
were followed for 2 months.
Biochemical analyses
Blood samples were obtained after a 14-hour fast at baseline
and after 2months of liraglutide therapy. They were centrifuged
within 30 minutes of collection, and aliquots were made of both
serumand plasma. All biochemical analyseswere run blinded on
never-frozen samples, with the exception of HO-1 and ghrelin
concentrations, which were measured on aliquots immediately
frozen and stored at 80° C.
Preprandial plasma ghrelin concentrationsweremeasured by
ELISA, according to the manufacturer’s protocol (Bio Vendor)
(8). Serum LOOH levels were evaluated following the oxidation
of Fe2 to Fe3 in the presence of xylenol orange at 560 nm (9).
The limit of detection for this assay was 0.025 nmol/L. Levels of
GSH were measured in serum using a spectrophotometric assay
based on the reaction of thiol groups with 2,2-dithio-bis-nitro-
benzoic acid (10). The production of ROS was assessed using
fluorescent probe dihydroethidium staining (Sigma) (11). Heat
shock protein 60 (Hsp60) and HO-1 concentrations were as-
sessed by ELISA using commercial kits (Enzo Life Science AG),
as previously described (12). Intra- and interassay coefficients of
variation were less than 10% for measurements of both Hsp60
and HO-1.
Statistical analysis
Statistical analysis was performed using Statview 5.0 (SAS
Institute). Univariate analysis was performed using paired t test.
We used the Spearman rank correlation method to evaluate
whether changes in cardio-metabolic risk factorswere associated
with changes in other measured parameters. All variables were
tested for normality performing the Kolmogorov-Smirnov nor-
mality test. Because concentrations of LOOH, ghrelin, HO-1,
and Hsp60 were not normally distributed; the nonparametric
Wilcoxon test was performed for these variables.
Results
None of the subjects discontinued metformin or liraglu-
tide, and the dosages of antihypertensivemedications, lip-
id-lowering agents, and aspirin remained unchanged dur-
Table 1. Patients’ Baseline Characteristics (n  20)
Characteristic
Age, y 57  13
Women, n (%) 10 (50)
Diabetes duration, y 6  3
Smoking habit, n (%) 2 (10)
Family history of cardiovascular diseases, n (%) 13 (65)
Systolic blood pressure, mm Hg 129  18
Diastolic blood pressure, mm Hg 78  8
Hypertension, n (%) 15 (75)
Dyslipidemia, n (%) 16 (80)
Obesity,a n (%) 4 (20)
Diabetic complications, n (%) 1 (5)
Use of anti-hypertensive therapies, n (%) 15 (75)
Use of lipid-lowering drugs, n (%) 10 (50)
Aspirin use, n (%) 9 (45)
a Obesity: BMI30.
The data are presented as mean  SD or n (%).
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ing the courseof the study.As shown inTable2, liraglutide
therapy led to significant reductions in HbA1c, ghrelin,
and GSH, with a concomitant decrease in LOOH and
HO-1. Further (data not shown), we found inverse cor-
relations between ghrelin and waist circumference (r 
0.467, P .0379), as well as between LOOH and total
and low-density lipoprotein (LDL) cholesterol (r 
0.498, P  .0254 and r  0.468, P  .0376, respec-
tively).Hsp60 inversely correlatedwithROS (r0.495,
P .0263). No other significant correlations between the
evaluated parameters were found.
Discussion
This is the first study evaluating the effect of liraglutide on
parameters of oxidative stress, ghrelin,HO-1, andHsp-60
in T2DM patients. Consistent with data from animal
models (13), we found that liraglutide reduced lipid per-
oxidation as measured by LOOH formation. However,
we did not find any significant effect on plasmaROS levels
in contrast with Okada et al (7), who recently reported
that liraglutide decreased diacron-reactive oxygenmetab-
olites in Japanese subjects with T2DM. In addition, we
found that liraglutide significantly increased plasma GSH
content, inconsistent with previous observations showing
that GLP-1 treatment may increase antioxidative activity
by a reduction in the oxidized GSH/total GSH ratio (14).
However, whether this effect is mediated by an increased
expression or activity of enzymes related to GSH biosyn-
thesis remains to be evaluated. Correlation analysis re-
vealed that liraglutide’s effects on oxidative stress seem to
be independent of glycemic control; therefore, changes in
LOOH and GSH were not associated with any change
found in other variables evaluated, with the exception of
an inverse correlation between LOOH and total or
LDL-cholesterol.
In vitro studies suggest that the antioxidant properties
of liraglutide may be linked to induction of HO-1, a mi-
crosomal enzyme able to suppress oxidative stress (12).
Oeseburg et al (15) have shown that GLP-1 can induce
increased expression of the oxidative stress defense gene
HO-1 in endothelial cells. Patients with T2DM have ab-
normal elevated plasma levels of HO-1 (16) and the pres-
ent study shows that liraglutide lowers its plasma concen-
trations. Correlation analysis revealed that changes in
HO-1were not associatedwith changes found in the other
evaluated parameters. Hsp60, human mitochondrial
chaperonin, is known to play an important role in cardio-
vascular homeostasis and has been associated with car-
diovascular risk (17).Wedidnot find any significant effect
of liraglutide onHsp60, despite a slightmean reduction in
its plasma levels. However, changes in Hsp60 levels were
inversely associated with changes in ROS.
Our findings show for the first time that liraglutide can
increase plasma ghrelin concentrations in patients with
T2DM. In another study, Senda et al (18) reported that
liraglutide restored ghrelin levels in a 25-year old woman
with the Prader-Willi syndrome. Liraglutide’s effect on
ghrelin may have an important indirect role on body
weight regulation, because ghrelin physiologically in-
creases during fasting and decreases after food intake [re-
viewed in Rizzo et al (4)]. This is supported by the inverse
association between changes in ghrelin and changes in
waist circumference in our subjects.
The strengths of our study include the blinded mea-
surements of all biochemical analyses, and the excellent
Table 2. Effects of 2 Months of Liraglutide Therapy in Subjects With Type 2 Diabetes
Characteristic Before Therapy After Therapy P
BMI, kg/m2 28.7  5.3 28.5  4.2 .6755
Waist circumference, cm 105  15 103  12 .1562
Fasting glycemia, mmol/L 8.7  3.6 7.6  2.2 .0756
HbA1c, % 8.5  0.4 7.5  0.4 .0001
Total Cholesterol, mmol/L 4.4  1.0 3.9  0.8 .0532
Triglycerides, mmol/L 1.9  0.7 1.7  0.5 .2358
HDL-cholesterol, mmol/L 1.1  0.3 1.1  0.2 .2226
LDL-cholesterol, mmol/L 2.5  0.9 2.0  0.7 .0752
LOOH, nmol/L 0.11  0.04 0.04  0.07 .0487
ROS, arbitrary units 6561  996 6379  1151 .5953
GSH, nmol/ml 0.36  0.06 0.44  0.07 .0002
Ghrelin, pg/ml 8.2  4.1 13.6  7.3 .0007
HO-1, ng/ml 7.7  7.7 3.6  1.8 .0445
Hsp60, ng/ml 7.1  5.7 6.6  4.8 .6149
Abbreviation: HDL, high-density lipoprotein.
The data are presented as means  SD.
The paired t test was used, except for concentrations of LOOH, ghrelin, HO-1, and Hsp60, which were not normally distributed; thus, the
nonparametric Wilcoxon test was performed.
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adherence to treatment intervention. A potential limita-
tion is the lack of a control group consisting of subjects on
metformin therapy alone. Previous studies have shown
that metformin administration has no appreciable effect
on ghrelin (19) and GSH concentrations (20) in subjects
with T2DM. It is therefore unlikely that metformin was
responsible for the significantmodulation of these param-
eters when administered with liraglutide, suggesting that
the changes were more likely attributable to the latter.
Further, the significant changes in the measured parame-
ters uponadding liraglutide reduce theprobability of these
findings occurring by chance alone. The coadministration
of other drugs for cardiovascular prevention (including
antihypertensive agents, statins, and aspirin) could affect
the measurements. However, the doses of these medica-
tions were kept essentially constant during the interven-
tion to avoid confounding. We did not perform any met-
abolic studies such as oral glucose tolerance ormixedmeal
tests, or evaluate parameters of cardiovascular function,
during the course of our pilot study.
In conclusion, we report novel metabolic effects of li-
raglutide in patients with T2DM. Our study is the first to
examine the effects of liraglutide on ghrelin, oxidative
stress and HO-1 and Hsp60 in patients with T2DM. The
improvement in these parameters independent of glycemic
control could contribute to reduced cardiovascular risk in
this patient population.
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